Drug Pricing Legislation In The US May Be Losing Momentum
Executive Summary
House subcommittee hearing on drug price negotiation bill championed by Speaker Nancy Pelosi showcases strong Republican opposition, and Senate Finance Committee Chairman Chuck Grassley suggests his bill may not be ready for a floor vote until next year.
You may also be interested in...
Lilly Isn't (Immediately) Worried About US Drug Pricing Legislation
Government price 'negotiations' unlikely to be enacted in the near term, CEO Ricks tells investors, but reform of the Part D benefit also faces long odds, even though Lilly would support well designed changes.
Medicare Part D Redesign Backed By House Republicans Retools Manufacturer Discount
Failed amendment offered by House Energy & Commerce Committee’s ranking Republican during markup of Speaker Nancy Pelosi’s drug pricing bill, the proposal is in line with biopharma’s position on manufacturer price concessions in Part D and suggests a road map for the kind of bill that might pass the Senate.
Beyond ICER: Arnold Foundation Wants To Dig Deeper On R&D And Pricing
Arnold Foundation VP Mark Miller explains how research into “what it costs to bring a drug to market” could supplement existing efforts to determine how prescription drug prices line up with value.